Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel Free PXMD Stock Alerts

PaxMedica (PXMD) Competitors

PaxMedica logo
$0.0005 0.00 (-28.57%)
As of 10:32 AM Eastern
Compare

PXMD vs. SCPS, GNCA, ARDS, GNCAQ, and EVLO

Should you buy PaxMedica stock or one of its competitors? PaxMedica's main competitors and comparable companies include Scopus BioPharma (SCPS), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Genocea Biosciences (GNCAQ), and Evelo Biosciences (EVLO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PaxMedica compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Scopus BioPharma's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

4.9% of PaxMedica shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scopus BioPharma has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
PaxMedica Neutral

Summary

Scopus BioPharma beats PaxMedica on 5 of the 6 factors compared between the two stocks.

How does PaxMedica compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Genocea Biosciences' return on equity of -182.88% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
PaxMedica N/A -3,167.89%-560.35%

PaxMedica has lower revenue, but higher earnings than Genocea Biosciences. PaxMedica is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
PaxMedica Neutral

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Genocea Biosciences beats PaxMedica on 6 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Aridis Pharmaceuticals?

PaxMedica (NASDAQ:PXMD) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Aridis Pharmaceuticals N/A N/A N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Aridis Pharmaceuticals Neutral

Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Aridis PharmaceuticalsN/AN/A-$30.37M-$0.02N/A

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.61, meaning that its share price is 4,661% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does PaxMedica compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
PaxMedica Neutral

4.9% of PaxMedica shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genocea Biosciences has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Summary

Genocea Biosciences beats PaxMedica on 4 of the 6 factors compared between the two stocks.

How does PaxMedica compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
PaxMedica Neutral

Evelo Biosciences has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

Evelo Biosciences is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Evelo Biosciences beats PaxMedica on 5 of the 8 factors compared between the two stocks.

Get PaxMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PXMD vs. The Competition

Export
MetricPaxMedicaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6K$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00631.84198.7718.91
Price / SalesN/A747.00565.6979.10
Price / CashN/A84.0876.6852.75
Price / Book0.009.1510.515.92
Net Income-$18.29M$2.82B$3.50B$380.90M
7 Day PerformanceN/A-4.55%-4.32%-4.38%
1 Month PerformanceN/A-8.50%-8.64%-7.25%
1 Year PerformanceN/A-6.15%2.05%-4.95%

PaxMedica Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PXMD
PaxMedica
N/A$0.00
-28.6%		N/AN/A$6KN/AN/A6
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$7KN/AN/A13
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A-50.0%$5KN/AN/A30
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PXMD) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...
Weiss Ratings | Sponsoredtc pixel
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...
Behind the Markets | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel